Jeisys ULTRAcel Q+
HIFU/Ultrasound Lifting · Linear+dot HIFU cartridge system
What it's actually cleared for: No 510(k); US gray-market resale documented
Last verified: August 6, 2026 · How we verify
New: —|Used: $10k–$20kmarket estimate, no email required
Bottom line
Jeisys Medical's HIFU — a top seller across Asia and Europe, distinguished by its linear cartridge that sweeps a line of thermal coagulation instead of firing single dots, meaning full-face treatment in as little as 10-15 minutes. Like the Ultraformer, it has NO US FDA clearance and reaches American buyers only through gray-market import, with used units brokering around $10k-18k. Jeisys is a serious manufacturer — its cleared US devices under other brands (Potenza's OEM, Density) prove the engineering pedigree — but the Q+ itself never went through a 510(k). Same calculus as the Ultraformer: proven tech abroad, regulatory homework at home.
Overview
Faster linear HIFU firing
How it works
The science
HIFU focuses at 1.5, 3.0, and 4.5mm (plus body depths) creating coagulation zones in dermis and SMAS, tightening immediately and stimulating collagen over 8-12 weeks. The Q+'s differentiator is its cartridge trio: classic dot cartridges for precision and linear cartridges delivering a continuous thermal line — cutting treatment time dramatically and, per Korean clinical reports, reducing pain scores. Later Jeisys platforms pair HIFU with RF; the international evidence base for facial laxity is solid. Visualization, as with all Ultherapy competitors, is absent.
Patented tech
The linear-firing HIFU cartridge is the signature IP — few competitors sweep a line rather than stamp dots — alongside the dot/linear/body cartridge interchange on one handpiece.
Origin
Seoul, South Korea (Jeisys Medical Inc.).
FDA & regulatory status
What it's actually cleared for:
No 510(k); US gray-market resale documented
Regulatory data is compiled from public FDA 510(k) records and may lag recent clearances. Always confirm status with the manufacturer before purchase.
Treatment economics
What practices charge
Internationally $700-1,500 full-face HIFU and $400-900 smaller zones, with the fast linear protocol enabling more treatments per day than dot-only platforms. Annual or semiannual retreatment sustains recurring revenue.
Consumables & recurring cost
Dot and linear cartridges are shot-limited consumables at ~$300-600 each via international suppliers; linear cartridges burn shots faster. Cartridge sourcing is the operational chokepoint for a US gray-market owner — counterfeits exist.
Ideal for
Best-fit practice
The sophisticated physician-led practice that has already cleared the insurance and state-board questions and wants HIFU speed as a competitive edge — often serving patients who know the ULTRAcel name from Korea. Not for new operators, delegating spas, or anyone unwilling to carry the regulatory posture knowingly.
Compliance
Medical director & delegation
Expect many medical directors to refuse association with a non-cleared energy device; those who proceed should require device-status disclosure in consent forms and tight protocols. Their license absorbs the downside — sign-off must be informed, not assumed.
Contraindications & screening
Pregnancy, implanted electrical devices, metal or filler in the focal plane, open lesions or active infection, care over the thyroid, brow, and marginal mandibular nerve territory. With no US manufacturer training available, seek instruction from experienced international users before treating.
Ownership
Warranty & service
No US manufacturer warranty or service network — you depend on the importing broker or independent biomedical techs, with parts shipped from Korea on their timeline. Budget for downtime and a service contingency fund.
Resale & used market
International demand keeps functioning units movable at roughly 40-55% of gray-market purchase price through broker channels. Domestic resale requires honest regulatory disclosure to the next buyer, which thins the US pool considerably.
Chains using this device
No confirmed chain deployments recorded yet.
Owner reviews
Write a reviewNo approved reviews yet. Be the first owner to publish one.
Alternatives
History
Every tracked change to pricing, lifecycle status, FDA data and warranty terms — newest first.
August 5, 2026
Editorial profile
Full profile published including US regulatory status — August 2026.
Source: Editorial (admin)
August 5, 2026
Warranty & service
No US manufacturer warranty or service network — you depend on the importing broker or independent biomedical techs, with parts shipped from Korea on their timeline. Budget for downtime and a service contingency fund.
Source: Automatic record update
August 1, 2026
Record created
Added to The Aesthetic Index — August 2026
Source: The Aesthetic Index editorial
Get the full State of Aesthetic Devices 2026 report
The first independent census of the US aesthetic device market — free.